

Infusion Therapy Order

Patient Name: _____ Date of Birth: _____

Address: _____ Height: _____ Weight: _____

Phone: _____ Allergies: _____

Primary Diagnosis: _____ ICD-10 Code: _____

Requested Infusion Start Date: _____ Frequency: _____

Infusion Location: _____ Duration: _____

Insurance Authorization: _____

Prescriber Information:

Prescriber Name: _____ NPI: _____

Address: _____

Phone: _____ Fax: _____

Prescriber Signature: _____

*****Please use a single line and mark through any orders you do not want if it is pre-checked...The Appointment request is required, but make edits to the Interval and Duration as needed...Please add any additional orders on the last page*****

SJH CANAKINUMAB (ILARIS)

version 3/11/2024

Appointment Request

	Interval	Defer Until	Duration
☐ SJH ONCBCN INJECTION APPOINTMENT REQUEST			
☐ Injection Appointment Request	Every 28 days	S	Until discont'd

Status: Future, Expected: S Approximate, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 2 days before or at most 2 days after

Appointment Request (continued)

		Interval	Defer Until	Duration
☐	SJH ONCBCN INJECTION APPOINTMENT REQUEST			
☐	Injection Appointment Request	Every 56 days	S	Until discontin'td
Status: Future, Expected: S Approximate, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 2 days before or at most 2 days after				

Provider Communication

		Interval	Defer Until	Duration
☒	SJH ONCBCN PROVIDER COMMUNICATION TB SCREENING			
☒	Physician communication order	Once	S	1 treatment
Normal				
☒	SJH ONCBCN PROVIDER COMMUNICATION CANAKINUMAB			
☒	Physician communication order	Every visit	S	Until discontin'td
Normal				

Nursing Communication

		Interval	Defer Until	Duration
☒	SJH ONCBCN NURSING COMMUNICATION - TB SCREENING			
☒	Nursing Communication	Once	S	1 treatment
Verify TB testing has occurred.				
☒	SJH ONCBCN NURSING COMMUNICATION - ACTIVE INFECTION			
☒	Nursing Communication	Every visit	S	Until discontin'td
Assess patient for signs and symptoms of active infections and notify physician if present. HOLD Treatment for active infections.				

Medications

		Interval	Defer Until	Duration
☐	SJH ONCBCN MED CANAKINUMAB 150 MG SUB-Q			

Medications (continued)

		Interval	Defer Until	Duration
☐	canakinumab (PF) (ILARIS) 150 mg/mL injection 150 mg	Every 28 days	S	Until discontinuation
	150 mg, subcutaneous, Once, Starting at treatment start time			
☐	SJH ONCBCN MED CANAKINUMAB 150 MG SUB-Q			
☐	canakinumab (PF) (ILARIS) 150 mg/mL injection 150 mg	Every 56 days	S	Until discontinuation
	150 mg, subcutaneous, Once, Starting at treatment start time			

Hypersensitivity Medications

		Interval	Defer Until	Duration
☒	SJH ONCBCN HYPERSENSITIVITY MEDS THERAPY PLAN			
☒	IV/CVAD Line Care	PRN	S	Until discontinuation
	Access existing central venous access device or insert peripheral IV as needed. Restart peripheral IV catheter (as needed) for any signs of redness, pain, swelling.			
☒	Deaccess/Discontinue CVAD	PRN	S	Until discontinuation
	No details available for preview			
☒	Oxygen Therapy -	PRN	S	Until discontinuation
	Clinic Performed, Status: Future, Expected: S, Expires: S+396 Start for any grade of reaction. O2 Delivery Method: Nasal cannula Titrate to saturation of: 92% Indications of O2: Other (see comments)			
☒	sodium chloride 0.9% (NS) infusion	PRN	S	Until discontinuation
	1,000 mL, intravenous, at 500 mL/hr, Once as needed, Hypersensitivity reaction, Starting when released Initiate infusion at 500 ml/hr. Titrate up to 999ml/hr to maintain SBP greater than 100.			
	Start for any grade of reaction.			
☒	diphenhydramine (BENADRYL) injection 50 mg	PRN	S	Until discontinuation
	50 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released Start for any grade of reaction.			
☒	famotidine (PEPCID) injection 20 mg	PRN	S	Until discontinuation
	20 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released Start for any grade of reaction.			
☒	dexamethasone (DECADRON) injection	PRN	S	Until discontinuation

	Interval	Defer Until	Duration
10 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released Give for Grade II - MODERATE symptoms or Grade III - SEVERE/Anaphylaxis Symptoms ☒ EPINEPHrine (ADRENALIN) HYPERSENSITIVITY USE PRN S Until discont'd injection 1 mg/mL 0.3 mg, intraMUSCULAR, Once as needed, Hypersensitivity reaction, Starting when released Do NOT administer via direct IV injection without dilution. Give for Grade III - SEVERE/Anaphylaxis Symptoms.			